Borysiewicz LK - Search Results

1

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC. Borysiewicz LK, et al. Lancet. 1996 Jun 1;347(9014):1523-7. doi: 10.1016/s0140-6736(96)90674-1. Lancet. 1996. PMID: 8684105 Clinical Trial.

2

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Lipetz C, Evans AS, Mason M. Adams M, et al. Vaccine. 2001 Mar 21;19(17-19):2549-56. doi: 10.1016/s0264-410x(00)00488-6. Vaccine. 2001. PMID: 11257391 Review.

3

Clinical studies of human papilloma vaccines in cervical cancer.

Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, Evans AS, Mason M. Adams M, et al. Adv Exp Med Biol. 2001;495:419-27. doi: 10.1007/978-1-4615-0685-0_61. Adv Exp Med Biol. 2001. PMID: 11774604 No abstract available.

4

Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.

Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Boursnell ME, et al. Among authors: borysiewicz lk. Vaccine. 1996 Nov;14(16):1485-94. doi: 10.1016/s0264-410x(96)00117-x. Vaccine. 1996. PMID: 9014288 Free PMC article.

5

Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes.

Evans EM, Man S, Evans AS, Borysiewicz LK. Evans EM, et al. Among authors: borysiewicz lk. Cancer Res. 1997 Jul 15;57(14):2943-50. Cancer Res. 1997. PMID: 9230206

6

Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III.

Nimako M, Fiander AN, Wilkinson GW, Borysiewicz LK, Man S. Nimako M, et al. Among authors: borysiewicz lk. Cancer Res. 1997 Nov 1;57(21):4855-61. Cancer Res. 1997. PMID: 9354449

7

Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.

Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V, Man S. Youde SJ, et al. Among authors: borysiewicz lk. Cancer Res. 2000 Jan 15;60(2):365-71. Cancer Res. 2000. PMID: 10667589

8

Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.

Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, Cerundolo V, Man S. Evans M, et al. Among authors: borysiewicz lk. J Immunol. 2001 Nov 1;167(9):5420-8. doi: 10.4049/jimmunol.167.9.5420. J Immunol. 2001. PMID: 11673561

9

Gene therapy and viral vaccination: the interface.

Wilkinson GW, Borysiewicz LK. Wilkinson GW, et al. Among authors: borysiewicz lk. Br Med Bull. 1995 Jan;51(1):205-16. doi: 10.1093/oxfordjournals.bmb.a072947. Br Med Bull. 1995. PMID: 7767644 Review.

10

HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function.

Thomas KJ, Smith KL, Youde SJ, Evans M, Fiander AN, Borysiewicz LK, Man S. Thomas KJ, et al. Among authors: borysiewicz lk. Int J Cancer. 2008 Jun 15;122(12):2791-9. doi: 10.1002/ijc.23475. Int J Cancer. 2008. PMID: 18366058 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

103 results

Search Page